Amneal Pharmaceuticals Inc (AMRX) 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31...

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

- Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD® - Lenalidomide capsules, referencing REVLIMID® Amneal Pharmaceuticals, Inc...

Form 4 - Statement of changes in beneficial ownership of securities

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Approval of three important therapies for dementia, oncology and gastrointestinal disease Granted 180-day exclusivity for memantine/donepezil...